Initial Public Offering

Xbiotech Logo


Price and Offering Terms





Trade &

April 14 & April 17, 2015



Interested XBIT Shares?*
Need Help or Have Questions? Call us.

... or have us contact you directly

*Subject to investor suitability considerations and investment objectives.


Final Prospectus

dated April 14, 2015

Company Report

(Commissioned by XBiotech)

Free-Writing Prospectus filed pursuant to rule 433, dated March 27, 2015; Registration Statement No. 333-201813

All documents, including a transcript of the company video, have been filed with the Securities and Exchange Commission.

Company Video


XBiotech is a clinical-stage biopharmaceutical company engaged in discovering and developing “True Human™” monoclonal antibodies for treating a variety of diseases. True Human™ monoclonal antibodies are those which occur naturally in human beings—as opposed to being derived from animal immunization or otherwise engineered. We believe that naturally occurring monoclonal antibodies have the potential to be safer and more effective than their non-naturally occurring counterparts. While focused on bringing our lead product candidate, Xilonix™, to market, we also have developed a True Human™ discovery platform as well as a low cost, next generation manufacturing system.

The majority of our efforts to date have been concentrated on developing MABp1 (also known as Xilonix™), a therapeutic antibody which specifically neutralizes interleukin-1 alpha (IL-1α). IL-1α is a pro-inflammatory protein produced by leukocytes and other cells, where it plays a key role in inflammation. When unchecked, inflammation can contribute to the development and progression of a variety of different diseases, such as cancer, vascular disease, inflammatory skin disease, and diabetes. Our clinical studies have shown that blocking IL-1α with MABp1 may have a beneficial effect in several diseases.

We completed a Phase I/II clinical trial for MABp1 (Xilonix™) as a treatment for cancer at MD Anderson Cancer Center. The results of this study, published in Lancet Oncology in April 2014, found that in the 52 patients with metastatic cancer (18 tumor types) who participated, MABp1 was well tolerated, with no dose-limiting toxicities or immunogenicity. Moreover, within eight weeks of starting therapy many patients began to improve with respect to constitutional symptoms. An imaging method, known as dual energy X-ray absorptiometry (DEXA), revealed that many of the patients improved physically, in terms of gaining lean body mass (LBM); and patient reported outcomes documented that many were recovering from pain, fatigue and appetite loss. Finally, we found that in the patients with colorectal cancer, DEXA-measured recovery was associated with significant improvement in survival.

For the complete company overview, please download the Final Prospectus.


PLEASE NOTE: W.R. Hambrecht + Co., LLC urges you to read a company's prospectus thoroughly before participating in any offering. To receive a prospectus for this company, click on the link above, call 1-800-673-6476, fax 1-415-551-3123, or write to: 909 Montgomery Street, 3rd Floor, San Francisco, CA 94133.

Going public is a process that is highly regulated by the Securities and Exchange Commission and self-regulatory organizations. There are a number of regulatory steps that affect the length and closing date of an initial public offering. These are not controlled by W.R. Hambrecht + Co., LLC or the company going public.

Publication of the prospectus is not a recommendation by W.R. Hambrecht + Co., LLC that any particular investor should purchase the securities described in the prospectus or that the securities are a suitable investment for any particular investor.

Publication of the prospectus does not constitute an offer by W.R. Hambrecht + Co., LLC to sell to any person or a solicitation of an offer from any person to buy from W.R. Hambrecht + Co., LLC, the securities described in the registration statement and the prospectus.